Browse Technologies

• 
• 
• 
• 

Sjögren's syndrome (SjS) is a common and debilitating autoimmune disease, causing dry eye symptoms ranging from discomfort to dysfunction. Vanderbilt researchers have identified orally administered levocarnitine as a novel potential therapeutic for treating this condition.

The G-protein activated, inward-rectifying potassium (K+) channels, "GIRKs", are a family of ion channels that has been the focus of intense research interest for nearly two decades. GIRK has been shown to play important roles in the pathophysiology of diseases such as anxiety, epilepsy, Down's syndrome, pain perception and drug addiction. Here scientists at Vanderbilt developed the first truly potent, effective, and selective GIRK activator, ML297 (VU0456810) and demonstrated that ML297 is active in animal models of epilepsy. While the group is using ML297 to continue to explore the therapeutic benefits of GIRK modulation, they are continuing to develop more selective and druggable GIRK inhibitors from different scaffolds.

Researchers at Vanderbilt University have developed a technique to enhance immune cell activation by exposing cells to mechanical force while culturing. Proof-of-concept data indicate that activating immune cells with this method may improve therapeutic efficacy and reduce manufacturing expenses, making powerful CAR T cell therapies more accessible to patients in need.

There is currently no radiotherapy phantom capable of quantitatively assessing all components of an online adaptive radiotherapy (online ART) system in a comprehensive end-to-end test.Represented here is a novel, rigid phantom that can simultaneously evaluate an online ART system's image acquisition, deformable image registration, contour propagation, plan re-optimization, dose calculation, and beam delivery in a single process that is robust, quantitative, and convenient.